1 / 7

Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection ERADICATE Trial

Phase 2a. HIV Coinfection. Treatment Naïve and Treatment Experienced. Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection ERADICATE Trial. Source: Osinusi A, et al. 49 th EASL. 2014: Abstract O14. Ledipasvir-Sofosbuvir in GT1 with HIV Coinfection ERADICATE Trial : Features.

gerard
Download Presentation

Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection ERADICATE Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2a HIV Coinfection Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir in GT-1and HIV CoinfectionERADICATE Trial Source: Osinusi A, et al. 49th EASL. 2014: Abstract O14.

  2. Ledipasvir-Sofosbuvir in GT1 with HIV CoinfectionERADICATE Trial: Features Source: Osinusi A, et al. 49thEASL. 2014: Abstract O14.

  3. Ledipasvir-Sofosbuvir in GT1 with HIV CoinfectionERADICATE Trial: Study Design 0 12 16 24 Week SVR12 Ledipasvir- Sofosbuvir Antiretroviral Untreated (n = 13)CD4 count stable & HIV RNA < 500 copies/ml orCD4 > 500 cells/mm3 SVR4 SVR12 Ledipasvir- Sofosbuvir *Antiretroviral Treated (n = 37)CD4 > 500 cells/mm3 HIV RNA < 40 copies/mlCurrent ARVs ≥ 8 weeks Drug Dosing: Ledipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once daily*Antiretrovirals allowed: tenofovir, emtricitabine, efavirenz, rilpivirine, and raltegravir Source: Osinusi A, et al. 49th EASL. 2014: Abstract .

  4. Ledipasvir-Sofosbuvir in GT1 with HIV CoinfectionERADICATE Trial: Baseline Characteristics Source: Osinusi A, et al. 49th EASL. 2014: Abstract O14.

  5. Ledipasvir-Sofosbuvir in GT1 with HIV CoinfectionERADICATE Trial: Antiretroviral Regimens Source: Osinusi A, et al. 49th EASL. 2014: Abstract O14.

  6. Sofosbuvir-Ledipasvir in GT1 with HIV CoinfectionERADICATE Trial: Results Source: Osinusi A, et al. 49th EASL. 2014: Abstract O14.

  7. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related